{"slideshow_credits": null, "snippet": "Valeant and Pershing Square are planning to raise their offer for Allergan. | Profit at Goldman less easy to find. | A.I.G. trial puts Timothy F. Geithner on the hot seat. | Glencore\u2019s chief pursues Rio Tinto.", "abstract": "Valeant and Pershing Square are planning to raise their offer for Allergan. | Profit at Goldman less easy to find. | A.I.G. trial puts Timothy F. Geithner on the hot seat. | Glencore\u2019s chief pursues Rio Tinto.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Sydney", "role": "reported", "lastname": "EMBER", "rank": 1, "organization": ""}], "original": "By SYDNEY EMBER"}, "web_url": "http://dealbook.nytimes.com/2014/10/08/morning-agenda-another-twist-in-allergan-battle/", "lead_paragraph": null, "headline": {"main": "Morning Agenda: Another Twist in Allergan Battle", "kicker": "DealBook"}, "_id": "543523eb38f0d86add490f64", "word_count": "2031", "multimedia": [], "pub_date": "2014-10-08T07:44:57Z", "source": "The New York Times", "news_desk": "Business", "keywords": [], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}